Aryl-chloro-ethyl ureas

Abstract

Described herein are novel 1-aryl-3-(2-chloroalkanylureas derivatives. These derivatives are useful anticaner agents having excellent specifilty towards cell targets and potent antineoplastic activity without systemic toxicity derivatives mutagenicity. More specifically, the invention is directed to novel derivatives of the following formula: wherein R1 is C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 alkoxy, C1-C6 hydroxy alkyl, or C1-C6 halide; R2 is H, C1-C6 alky, C3-C7 cycloalkyl, C1-C6 I alkoxy, C1-C6 hydroxy alkyl or C1-C6 halide, di-halide or tri-halide; R1 and R2 may also be part of cyclic structures. R3 and R4 are as defined in R6 or, halide, di-halide, tri-halide, C1-C7 lower dialkyl, or alicyclic groups fused to the phenyl ring, these alicyclic ring can be substituted by one or more groups as defined in R6; or polycyclic rings bearing not more than three rings wherein the rings other than the ring bearing the substituted 2-chloroethylamino moiety can be substituted by one or more groups as defined in R6; R6 is H, C1-C7 alkyl, C1-C7 alkoxy alkyl, C1-C7 amino alkyl, C1-C6 thio alkyl, C1-C5 S-alkyl, C1-C7 N-alkyl, C1-C7 N,N-dialkyl, C1-C7 cyanoalkyl, C1-C7 haloalkyl, C1-C7 sulfoxide or C3-C7 cycloalkyl; or a prodrug thereof Also disclosed are pharmaceutical compositions containing the compounds of the invention in conjunction with a pharmaceutically acceptable carrier and the use of the compositions in treating cancer.

Dependencies are inferred from the claim text.